NCT07157722Not yet recruitingPhase 3
Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia
The Potential Role of N-Acetyl Cysteine or Alpha-Lipoic Acid as Adjuvant Therapies in the Treatment of Patients With Beta Thalassemia
Source: ClinicalTrials.gov · Last updated 5 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 28 Aug 2025
- Start date
- 30 Aug 2025
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Tanta University
- Diseases
- Thalassaemia
- NCT number
- NCT07157722
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 66
- From 30 Aug 2025 to the primary completion date, 30 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a prior history of significant cardiovascular diseases, such as coronary artery disease, myocardial infarction, or stroke.
- Patients who will be non-compliant with the prescribed therapy.
- Patients who will receive antioxidant or anti-inflammatory medications.
Other illness
- Patients with familial hypercholesterolemia or history of premature atherosclerosis.
- Patients with diabetes.
- Patients with inflammatory diseases, such as Systemic lupus erythematous, rheumatoid arthritis and inflammatory bowel disease.
- Patients with oxidative stress related diseases, such as Alzheimer, Parkinson, COPD and cancer.
Other
- Patients with severe renal dysfunction.
- Patients with severe hepatic dysfunction.
- Patients with other hemoglobinopathies.
- Pregnant women.
- Obese patients.
Who the study is looking for
- Patients with beta-thalassemia who will receive conventional thalassemia management.
- Both genders.
- Age ≥ 18 years old.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Pharmacy, Tanta University Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.